Company news

Clever Culture Systems Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

CCS Appoint Thermo Fisher as Exclusive European Distributor

December 18, 2022

Non-renounceable Rights Issue Results

November 28, 2022

Rights Issue Prospectus

October 24, 2022

Non-Renounceable Rights Issue

October 24, 2022

$1.5M Funding Awarded for New APAS Instrument

October 23, 2022

Direct Sale of APAS Independence in United States

May 3, 2022

Purchase Order for Multiple APAS Instruments

March 15, 2022

LBT Investor Call to discuss CCS Acquisition

January 10, 2022

LBT Completes CCS Acquisition

January 3, 2022

LBT to Obtain Full Ownership of CCS Joint Venture

December 28, 2021

Market Update - Sales Pipeline and Evaluations

December 7, 2021

US FDA 510(k) Clearance for MRSA Analysis Module

October 28, 2021

CCS Appoints Thermo Fisher as Exclusive US APAS Distributor

September 26, 2021

Appendix 4E and Annual Financial Statements

August 26, 2021

APAS Independence Sales to Health Services Laboratory, UK

May 17, 2021

Appendix 4C - quarterly

April 28, 2021

Market Update - Board Renewal Process

January 31, 2021

$0.75m Funding Awarded for APAS-AMR Analysis Module

September 2, 2020

Oneservice Appointed Managed Service Provider for APAS

July 13, 2020

Proposed issue of Securities - LBT

July 8, 2020

$8M private placement & launch of spp

July 8, 2020

Trading Halt

July 7, 2020

LBT teams with global clinical diagnostics company

July 6, 2020

Results of Evaluation of APAS Independence by Johns Hopkins

June 30, 2020

First Sale of APAS Independence in United States

June 8, 2020

Update on MRSA Analysis Module US FDA Submission

June 3, 2020

$1.5M Draw Down on South Australian Government Loan

May 25, 2020

South Australian Government Agree to Extend Loan Facility

May 7, 2020

Presentation at NWR Virtual Small Cap Conference

April 29, 2020

US FDA 510(k) Submission for MRSA Analysis Module

March 29, 2020

VRE Analysis Module - Clinical Study Commenced

March 19, 2020

Johns Hopkins Hosp to Present Study Data APAS Independence

March 11, 2020

LBT Receives $1.1 Million R&D Tax Incentive

January 21, 2020

Presentation at Biotech Showcase Investor Conference

January 13, 2020

CEO Presentation - AGM 2019

November 27, 2019

Chairmans Address to Shareholders

November 27, 2019

Non-Executive Director Retirement

October 30, 2019

First European Sale of APAS Independence

October 21, 2019

LBT Presents at ExchangeSA Conference in Adelaide

September 25, 2019

MRSA Analysis Module CE Mark Registration

September 24, 2019

European Union Regulatory Certification & MRSA Study Results

September 15, 2019

Appendix 4E Full Year Report

August 29, 2019

Update on Distributor Appointments

July 21, 2019

South Australian Government Loan $1.5M Drawdown

June 26, 2019

First U.S. Clinical Data with APAS Presented at ASM Microbe

June 23, 2019

US Market Update

June 18, 2019

Information Required Under ASX Listing Rule 3.10.5A

June 11, 2019

$5M Oversubscribed Private Placement

June 5, 2019

APAS Independence Receives US FDA 510(k) Clearance

May 20, 2019

South Australian Government Loan - $1.0M Drawdown

May 8, 2019

← Newer news releases · Older news releases →

Decks

The 5 newest of 12 decks. Every deck is listed under its year.